Rezolute receives priority medicines (prime) eligibility from european medicines agency for enhanced regulatory support of rz358 in congenital hyperinsulinism

Prime eligibility granted based on key positive data from the phase 2b (rize) study and current unmet medical need in congenital hyperinsulinism prime eligibility granted based on key positive data from the phase 2b (rize) study and current unmet medical need in congenital hyperinsulinism
RZLT Ratings Summary
RZLT Quant Ranking